Get the Stockscreener App
8.39
7.29%
0.57
After Hours:
8.41
0.02
+0.24%
Immunitybio Inc stock is traded at $8.39, with a volume of 30.48M.
It is up +7.29% in the last 24 hours and up +41.13% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.82
Open:
$8.21
24h Volume:
30.48M
Relative Volume:
0.90
Market Cap:
$8.63B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-21.52
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-3.23%
1M Performance:
+41.13%
6M Performance:
+222.69%
1Y Performance:
+189.31%
1-Day Range:
$8.20
$8.91
1-Week Range:
$7.77
$8.91
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.39 | 8.63B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells’ - Insider Monkey
Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge - Yahoo Finance
ImmunityBio’s European Expansion Boosts Market Reach - timothysykes.com
IBRX Stock Rises 9%: ImmunityBio Reports Breakthrough In NK Cell Therapy Production - Stocktwits
ImmunityBio’s Market Expansion Amidst Financial Challenges - StocksToTrade
ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus - TechStock²
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking - Yahoo Finance
ImmunityBio Valuation: Paying 33x Sales for Anktiva - TradingView
IBRX Stock: Anktiva's Approvals and What Comes Next - TradingView
ImmunityBio updates on cell therapy programs (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Expands Reach with European Approval, IBRX Stock Gains Momentum - timothysykes.com
ImmunityBio Shares Surge 295% Year-to-Date: Should You Buy, Hold, or Sell? - Bitget
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors - Investing News Network
Why ImmunityBio Stock Is Soaring Today - AOL.com
Why Is ImmunityBio Stock Soaring On Friday? - Benzinga
IMMUNITYBIO, INC. (IBRX) - MSN
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell? - TradingView
ImmunityBio completes NK cell manufacturing programs - Investing.com
Single apheresis yields 5B NK cells in ImmunityBio cancer program - Stock Titan
Assessing ImmunityBio (IBRX) Valuation After FDA Acknowledges Resubmitted ANKTIVA Bladder Cancer Filing - Sahm
IBRX Stock: Anktiva Receives Approvals and Future Steps Ahead - Bitget
ImmunityBio’s (IBRX) Bladder Cancer sBLA Resubmission Tests The Depth Of Its Immuno‑Oncology Strategy - simplywall.st
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.2%What's Next? - MarketBeat
Immunitybio stock initiated at Buy by BTIG with $13 target - Investing.com
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst - Stocktwits
IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits
IBRX Stock Falls -23% In 6-Day Spree On Profit-Taking After 500% YTD Gain - Trefis
ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation - timothysykes.com
ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - marketscreener.com
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge - simplywall.st
FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story - Yahoo Finance
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) - Bitget
IBRX stock declines — ImmunityBio resubmits Anktiva application to FDA with additional data - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 2.5%Should You Sell? - MarketBeat
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Bitget
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data - The Malaysian Reserve
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Asianet Newsable
ImmunityBio Stock Sinks as FDA Review Drags On - TipRanks
ImmunityBio resubmits bladder cancer application to FDA - Investing.com
ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG - TipRanks
FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan
ImmunityBio’s Stock Sees a Huge Boost - Los Angeles Business Journal
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):